Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Pregnancy

Risk Assessment & Treatment in Antiphospholipid Syndrome Patients

Thomas R. Collins  |  July 18, 2019

CHICAGO—Choosing a treatment for antiphospholipid syndrome (APS) involves an array of factors, from the antibodies present to their titers to other risk factors, said Lisa Sammaritano, MD, during a guided tour of APS treatment at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7. Dr. Sammaritano, associate attending physician at the Hospital for Special Surgery,…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Antiphospholipid Antibody Syndrome (APS)Hughes Syndrome

Research Advances Continue in the Fight Against Lupus

Larry Beresford  |  June 17, 2019

SAN FRANCISCO—The 13th International Congress on Systemic Lupus Erythematosus (SLE), held April 5–8, highlighted continuing advances in the fight against lupus, a chronic, inflammatory, autoimmune disease affecting multiple organ systems. The rheumatologist’s ability to control this incurable and life-threatening condition is limited both by its heterogeneous presentation and by the lack of successful treatment options,…

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:International Congress of Lupustargeted immune modulatortargeted therapy

Risk Assessment & Treatment in APS Patients

Thomas R. Collins  |  June 12, 2019

The pathogenesis of antiphospholipid syndrome (APS) is complicated and may involve local inflammation, vasculopathy, pregnancy complications and thrombosis. During the 2019 ACR State-of-the-Art Clinical Symposium, Lisa Sammaritano, MD, addressed the risk assessment and treatment of APS patients…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:2019 State-of-the-Art Clinical SymposiumAntiphospholipid Antibody Syndrome (APS)Hughes Syndromeriskrisk assessmentthrombosis

Myositis Autoantibodies as Biomarkers

Lara C. Pullen, PhD  |  June 4, 2019

A recent study details the autoantibodies of patients with myositis, confirming most patients carry these antibodies. The results also describe how myositis-specific autoantibodies can be used to identify distinct clinical subsets of idiopathic inflammatory myopathy…

Filed under:ConditionsMyositis Tagged with:autoantibodiesidiopathic inflammatory myopathiesILDInterstitial Lung Diseasemyositis

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

Michele B. Kaufman, PharmD, BCGP  |  May 7, 2019

Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…

Filed under:Biologics/DMARDsDrug Updates Tagged with:breastfeedingCanadaCertolizumab PegolNICEplaque psoriasispregnant womenU.K.

Addicted to Learning: Can We Teach as Well (& Enthrallingly!) as Fortnite?

Philip Seo, MD, MHS  |  April 15, 2019

My nephew is an addict. These words do not come easily to me, but I have come to accept them as true. In retrospect, I should have recognized the telltale signs: He stopped picking up the phone when I call. He disappears and then re-emerges hours later, seemingly having done nothing. He has lost interest…

Filed under:Education & TrainingOpinionRheuminationsSpeak Out Rheum Tagged with:augmented realitymassive open online course (MOOC)virtual reality

Antiphospholipid Antibody Syndrome: Much Remains to be Learned

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—Antiphospholipid antibody syndrome (APS) mainly affects young women, but can also affect men. APS patients test positive for multiple antibodies, including lupus anticoagulant (LAC), anti-cardiolipin and/or anti-beta2-glycoprotein I. These antibodies are diagnostic of APS, and they place the patient at increased risk for thrombosis and, in women, pregnancy morbidity. Women with LAC or those who…

Filed under:ConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:2018 ACR/ARHP Annual MeetingAntiphospholipid Antibody Syndrome (APS)Hughes Syndrome

Awards, Appointments & Announcements in Rheumatology

Ann-Marie Lindstrom  |  February 18, 2019

2018 Evelyn V. Hess Award The Evelyn V. Hess Award is given annually to recognize the exceptional contributions of a clinical or basic researcher whose body of work has advanced the understanding of the science of lupus treatment. At a reception during the 2018 ACR/ARHP Annual Meeting in Chicago, the Lupus Foundation of America presented…

Filed under:AwardsProfiles Tagged with:Dr. J. Michelle KahlenbergDr. Michelle PetriDr. Susan ManziEvelyn V. HessLupus FoundationMary Betty Stevens Young Investigator PrizeStevan Gibson

Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus

Lara C. Pullen, PhD  |  February 18, 2019

CHICAGO—The correct dosing of hydroxychloroquine (HCQ) for systemic lupus erythematosus (SLE) is a concern of all rheumatologists. Petros Efthimiou, MD, clinical professor of medicine at New York University, New York City, opened the Great Debate of the 2018 ACR/ARHP Annual Meeting by stating, “Today, we will be discussing a critical clinical problem that affects everyone’s…

Filed under:Drug UpdatesMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingGuidelinesHydroxychloroquine (HCQ)

The ACR Has Introduced a New Reproductive Health Guideline Draft

Susan Bernstein  |  January 17, 2019

CHICAGO—Reproductive health can be a concern for patients with rheumatic diseases, and practitioners in both disciplines often work closely together. The Reproductive Health in Rheumatic and Musculoskeletal Diseases Guideline, a draft of new clinical recommendations developed by an ACR-convened group for pregnant women, post-menopausal women, lactating women, and women and men trying to conceive or…

Filed under:Clinical Criteria/GuidelinesMeeting Reports Tagged with:deficiency of adenosine deaminase 2 (DADA2)Dr. Chip Chamberspolyarteritis nodosa

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences